机译:一种新的口服抗凝血剂在特定种群中的进展和应用:Dabigatran eXexilate
Soochow Univ Affiliated Hosp 2 Dept Pharm Suzhou Jiangsu Peoples R China;
Soochow Univ Affiliated Hosp 2 Dept Pharm Suzhou Jiangsu Peoples R China;
Soochow Univ Affiliated Hosp 2 Dept Pharm Suzhou Jiangsu Peoples R China;
Dabigatran etexilate; novel oral anticoagulants; pharmacokinetics; clinical trials; drug interactions; specific populations; NVAF;
机译:一种新的口服抗凝血剂在特定种群中的进展和应用:Dabigatran eXexilate
机译:直接凝血酶抑制剂达比加群及其口服活性前药达比加群酯的体外概况和离体抗凝活性。
机译:抗凝治疗的新视野:达比加群酯化一种新型口服抗凝药
机译:抗凝血剂对AEDES(DIPTERA:CULICIDAE)口服登革热病毒-3的喂养率,死亡率和感染率和感染率的影响
机译:在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
机译:坚持新的口服抗凝治疗处方:达比加群酯
机译:抗凝治疗的开阔视野:达比加群酯化一种新型口服抗凝剂